Biomarker ID | 1038 |
PMID | 23322201 |
Year | 2013 |
Biomarker | Alanyl membrane aminopeptidase (ANPEP) |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethylated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Renin-angiotensin system, SARS coronavirus protease, Dendritic cells in regulating TH1 and TH2 development, Glutathione metabolism, C-Myb transcription factor network |
Experiment | Prostate Cancer Vs Non Malignant Tissue |
Type of Biomarker | Diagnostic |
Cohort | Clinical sample set, consisting of 10 localised PC (LPC), 10 metastatic PC (MPC), and 10 nonmalignant prostate tissue samples (5 Adjacent normal and 5 Bengin Prostatic Hyperplasia) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.0023 |
Method Used | Genomic bisulphite sequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |